|
1
|
Wolach O and Stone RM: Optimal therapeutic
strategies for mixed phenotype acute leukemia. Curr Opin Hematol.
27:95–102. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Weinberg OK and Arber DA: Mixed-phenotype
acute leukemia: Historical overview and a new definition. Leukemia.
24:1844–1851. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H and Thiele J (eds): WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues. Vol 2. Revised 4th
edition. IARC Publications, Lyon, 2017.
|
|
4
|
Matutes E, Pickl WF, Van't Veer M, Morilla
R, Swansbury J, Strobl H, Attarbaschi A, Hopfinger G, Ashley S,
Bene MC, et al: Mixed-phenotype acute leukemia: Clinical and
laboratory features and outcome in 100 patients defined according
to the WHO 2008 classification. Blood. 117:3163–3171.
2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Weinberg OK, Seetharam M, Ren L, Alizadeh
A and Arber DA: Mixed phenotype acute leukemia: A study of 61 cases
using World health organization and European Group for the
immunological classification of leukaemias criteria. Am J Clin
Pathol. 142:803–808. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Weir EG, Ali Ansari-Lari M, Batista DA,
Griffin CA, Fuller S, Smith BD and Borowitz MJ: Acute bilineal
leukemia: A rare disease with poor outcome. Leukemia. 21:2264–2270.
2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wang Y, Gu M, Mi Y, Qiu L, Bian S and Wang
J: Clinical characteristics and outcomes of mixed phenotype acute
leukemia with Philadelphia chromosome positive and/or bcr-abl
positive in adult. Int J Hematol. 94:552–555. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shimizu H, Yokohama A, Hatsumi N, Takada
S, Handa H, Sakura T and Nojima Y: Philadelphia chromosome-positive
mixed phenotype acute leukemia in the imatinib era. Eur J Haematol.
93:297–301. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Park HW, Lee JH, Choi SJ, Lee JH, Seol M,
Lee YS, Ryu SG, Kim KH, Jang H, Seo EJ, et al: Hypoplastic acute
myeloid leukemia. Blood. 108(4493)2006.
|
|
10
|
Needleman SW, Burns CP, Dick FR and
Armitage JO: Hypoplastic acute leukemia. Cancer. 48:1410–1414.
1981.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Berdeaux DH, Glasser L, Serokmann R, Moon
T and Durie BG: Hypoplastic acute leukemia: Review of 70 cases with
multivariate regression analysis. Hematol Oncol. 4:291–305.
1986.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Killick S, Matutes E, Powles RL, Hamblin
M, Swansbury J, Treleaven JG, Zomas A, Atra A and Catovsky D:
Outcome of biphenotypic acute leukemia. Haematologica. 84:699–706.
1999.PubMed/NCBI
|
|
13
|
Legrand O, Perrot JY, Simonin G, Baudard
M, Cadiou M, Blanc C, Ramond S, Viguié F, Marie JP and Zittoun R:
Adult biphenotypic acute leukaemia: An entity with poor prognosis
which is related to unfavourable cytogenetics and P-glycoprotein
over-expression. Br J Haematol. 100:147–155. 1998.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Heesch S, Neumann M, Schwartz S, Bartram
I, Schlee C, Burmeister T, Hänel M, Ganser A, Heuser M, Wendtner
CM, et al: Acute leukemias of ambiguous lineage in adults:
Molecular and clinical characterization. Ann Hematol. 92:747–758.
2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kawajiri C, Tanaka H, Hashimoto S, Takeda
Y, Sakai S, Takagi T, Takeuchi M, Ohwada C, Sakaida E, Shimizu N
and Nakaseko C: Successful treatment of Philadelphia
chromosome-positive mixed phenotype acute leukemia by appropriate
alternation of second-generation tyrosine kinase inhibitors
according to BCR-ABL1 mutation status. Int J Hematol. 99:513–518.
2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Takata H, Ikebe T, Sasaki H, Miyazaki Y,
Ohtsuka E, Saburi Y, Ogata M and Shirao K: Two elderly patients
with philadelphia chromosome positive mixed phenotype acute
leukemia who were successfully treated with dasatinib and
prednisolone. Intern Med. 55:1177–1181. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Satake A, Okada M, Asada T, Fujita K,
Ikegame K, Tamaki H, Fujimori Y and Ogawa H: Dasatinib is effective
against optic nerve infiltration of Philadelphia
chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma.
51:1920–1922. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Townsend JH, Dubovy SR, Pasol J and Lam
BL: Transient optic perineuritis as the initial presentation of
central nervous system involvement by pre-B cell lymphocytic
leukemia. J Neuroophthalmol. 33:162–164. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Quann KA and Redner RL: The eyes have it:
CNS leukemia presenting as optic neuritis. Int J Hematol.
113:311–312. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Myers KA, Nikolic A, Romanchuk K, Weis E,
Brundler MA, Lafay-Cousin L and Costello F: Optic neuropathy in the
context of leukemia or lymphoma: Diagnostic approach to a
neuro-oncologic emergency. Neurooncol Pract. 4:60–66.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Porkka K, Koskenvesa P, Lundán T,
Rimpiläinen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M,
Brethon B, et al: Dasatinib crosses the blood-brain barrier and is
an efficient therapy for central nervous system Philadelphia
chromosome-positive leukemia. Blood. 112:1005–1012. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gotoh A and Broxmeyer HE: The function of
BCR/ABL and related proto-oncogenes. Curr Opin Hematol. 4:3–11.
1997.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fukunaga A, Sakoda H, Iwamoto Y, Inano S,
Sueki Y, Yanagida S and Arima N: Abrupt evolution of Philadelphia
chromosome-positive acute myeloid leukemia in myelodysplastic
syndrome. Eur J Haematol. 90:245–249. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Keung YK, Beaty M, Powell BL, Molnar I,
Buss D and Pettenati M: Philadelphia chromosome positive
myelodysplastic syndrome and acute myeloid leukemia-retrospective
study and review of literature. Leuk Res. 28:579–586.
2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Islam A: Hypoplastic acute myeloid
leukemia in an elderly patient. A long-term partial remission with
low-dose prednisone and G-CSF. Clin Case Rep. 7:1285–1290.
2019.PubMed/NCBI View Article : Google Scholar
|
